

1 **Cell Line Exemptions**

2
3 **Note: Italicised text in the box is background for the reader and will not be added to the**
4 **TCPS.**

5
6 **Exemption from REB review for de-identified cell lines**

7
8 **Note: Italicised text in the box is background for the reader and will not be added to the**
9 **TCPS.**

10
11 *Research involving human cell lines falls within the TCPS 2 (2018) definition of “research*
12 *involving humans.” As such, it is subject to review by an REB ([Article 2.1](#)). Current TCPS*
13 *guidance is intended to protect the privacy of the donor (the “participant”) from whose tissue*
14 *the cell line was derived and to respect the terms they consented to, if any, for the use of their*
15 *human biological materials.*

16
17 *Research involving the creation of a cell line requires REB review. However, REB review of*
18 *research involving the re-use of an existing de-identified (see Glossary below) cell line may not*
19 *increase protection for participants and may unnecessarily burden researchers and REBs. Risks*
20 *to privacy are low if the researcher does not know or have access to the identity of the*
21 *participant (b). Risks are even lower if the research is unlikely to reveal the identity of the*
22 *participant (d) and the researcher will not take any steps to identify the participant (c).*

23
24 *If consent terms are known to the researcher, they must comply with them to ensure respect for*
25 *participant autonomy (a). However, this is rarely the case with the re-use of de-identified cell*
26 *lines. In the case of anonymized cell lines, the participant identity and the terms of their consent*
27 *are unknown. In the case of coded cell lines, the source of the cell lines, typically a biobank, is*
28 *responsible for ensuring the researcher’s re-use of its cell lines are consistent with the terms of*
29 *participant consent.*

30
31 *The Panel on Research Ethics proposes the following exemption from REB review, which*
32 *balances the benefits to society of cell line research with low risks for participants.*

33
34 The following article exempts from REB review research involving the re-use of somatic cell
35 lines where privacy concerns are low and where REB review would not add any further
36 protections for research participants beyond those already provided by the source of the cell
37 lines.

38
39 ***Article X***

40
41 REB review is not required for research that relies exclusively on the re-use of de-identified
42 human somatic cell lines where:

- 43 a) the researcher will comply with known consent terms;
44 b) the researcher does not know or have access to the identity of the participant;
45 c) the researcher will not take any steps to identify the participant; and
46 d) the research is unlikely to reveal the identity of the participant.

47 ***Application***

48
49 All members of the research team must comply with the conditions in Article X for the
50 exemption to apply. Researchers must consider all stages of the research when determining
51 whether it meets the conditions of the exemption, including, for example, analysis and results
52 dissemination. When in doubt about the applicability of this exemption, researchers should
53 consult their REBs. Explanations of the terms used in the exemption can be found in the
54 Glossary section below.

55 Should any of the conditions described in Article X change during the conduct of the research,
56 the researcher must seek REB review in a timely manner, because the risks to the participant will
57 have increased if the terms of the exemption are not fulfilled. The urgency of seeking REB
58 review after it has been determined that a condition of Article X has changed is commensurate
59 with the level of risk that the change presents to participant welfare. REBs should consider the
60 issues relevant to participant protection such as how the participant identity was revealed, to
61 whom, and how participant privacy will be protected going forward. Consideration should be
62 given as to whether consent can and should be sought from the participant for the research to
63 continue.

64
65 The exemption in Article X does not invalidate other TCPS articles that may apply to the
66 research being considered. The following are two examples. Research involving the derivation of
67 induced pluripotent stem cells that will be transferred into humans or animals requires REB
68 review ([Article 12.10](#)). Research involving the re-use of human biological materials, identifiable
69 as originating from an Indigenous community, within Canada or internationally, requires REB
70 review ([Article 9.20](#)). Note that the TCPS definition of human biological materials includes cell
71 lines ([Article 2.1](#)).

72
73 Researchers who create cell lines, and who know the identity of the participant, will not meet the
74 terms of the exemption for the re-use of those cell lines because they will not meet condition (b)
75 of Article X. They should therefore consider at the outset whether they plan to re-use these cell
76 lines, and if so, seek REB approval (and participant consent, where applicable) for re-use at the
77 time of the initial ethics review.

78
79 Researchers are also responsible for ascertaining and complying with all applicable legal and
80 regulatory requirements with respect to consent and the protection of privacy of participants
81 ([Chapter 5](#)).¹

82
83 ***Glossary***

84 The following are more detailed explanations of terms used in the exemption:

85

86 ***Cell line***

¹ These legal and regulatory requirements may vary depending on the jurisdiction in Canada in which the research is being conducted, and who is funding and/or conducting the research. They may comprise constitutional, statutory, regulatory, common law, and/or international or legal requirements of jurisdictions outside of Canada (Chapter 1, Section C).

87 Cells may be obtained from tissue and placed into culture in order to proliferate. When
88 these cells can no longer proliferate because they have taken up all the nutrients in the
89 primary culture, they can be transferred to a new culture to allow for continued growth, a
90 process called subculturing. A cell line is the progeny of a primary culture when it is
91 subcultured (Geraghty, et al., *Guidelines for the use of cell lines in biomedical research*).

92 *De-identified (anonymized or coded)*

93 De-identified cell lines are those from which direct identifiers of specific individuals have
94 been removed. They include anonymized cell lines and coded cell lines where the
95 researcher does not have access to the key code.

96 Anonymized cell lines are cell lines that have been irrevocably stripped of direct
97 identifiers. Coded cell lines have had direct identifiers removed and replaced with a code
98 ([Chapter 12, Section A](#)).

99 *Relies exclusively*

100 “Relies exclusively” means that, from a human participation perspective, the research
101 only involves the human cell line. Research that involves the donor or other human
102 research participants in conjunction with the cell line requires REB review.

103 *Re-use*

104 The exemption applies to research that involves the re-use of cell lines that already exist,
105 for example, research involving a cell line that has been purchased from a commercial
106 biobank. For those familiar with TCPS terminology, “re-use” means the same as
107 “secondary use” in this context. “Re-use” is thought to be more generally understood by
108 those unfamiliar with TCPS terms and therefore less open to interpretation.

109 *Somatic*

110 A somatic cell is any body cell other than gametes (egg or sperm). Sometimes referred to
111 as “adult” cells ([TCPS Glossary](#)).

118 **Exemption from REB review for identified cell lines in the public domain**

119 **Note: Italicised text in the box is background for the reader and will not be added to the**
120 **TCPS.**

121
122 *In general, REB review is required for research involving the re-use of identified cell lines*
123 ([Article 12.3A](#)). However, if the cell line and the participant's identity are already in the public
124 domain, REB review would not address provenance or privacy issues in any meaningful way. If
125 it is impossible or impracticable to seek consent, there is no consent process that can be
126 reviewed by an REB. If the research is unlikely to cause new harm to the participant, the
127 research-attributable risk is minimal. If the research complies with consent terms, then REB
128 review offers them little additional protection.

129
130 *The example to which this article applies is the HeLa cell line. The HeLa cell line was derived*
131 *in the early 1950s, in Baltimore, from tissue that was obtained without consent from Henrietta*
132 *Lacks, who later died. In addition, her privacy was not protected. This is not consistent with*
133 *contemporary ethics requirements, both in the U.S. (under the Common Rule) and in Canada*
134 *(under the TCPS). Because of its ability to replicate itself, the HeLa cell line was and is widely*
135 *used in research. The scientific knowledge it helped acquire became the basis for many health-*
136 *related products that proved to be lucrative to the companies that developed them. However,*
137 *the Lacks family did not directly receive any of the benefits generated by its use.*

138 *Research using the HeLa cell line has resulted in benefits to society and the manner in which*
139 *the cells were initially collected has stimulated many thoughtful discussions about ethical*
140 *provenance. It is reported that the Lacks family is proud of what the cells have helped*
141 *accomplish (Arnst, [Sharing the Whole HeLa Genome](#), accessed July 14, 2020).*

142 The following article exempts from REB review research involving the re-use of identified
143 somatic cell lines that are already available and identified in the public domain, such as the
144 HeLa cell line.

145 ***Article Z***

146 REB review is not required for research that relies exclusively on the re-use of identified human
147 somatic cell lines where:

- 148 a) the cell line is already available and identified in the public domain;
- 149 b) it is impossible or impracticable to seek consent;
- 150 c) the researcher will comply with known consent terms; and
- 151 d) the research is unlikely to harm the participant.

152 ***Application***

153
154 Identified cell lines are those labelled with a direct identifier such as a name ([Chapter 12, Section](#)
155 [A](#)). Cell lines in the public domain are those available from public catalogues such as one would
156 find at a commercial biobank. Availability can range from freely available with no barrier at all,
157 to accessible if a researcher formally requests and is granted access in accordance with
158 established criteria, e.g., a materials transfer agreement.

159 Impracticable means incapable of being put into practice due to a degree of hardship or
160 onerousness that jeopardizes the conduct of the research; it does not mean mere inconvenience
161 ([TCPS Glossary](#)).

162 When considering whether research may harm participants, researchers must consider whether
163 anything about the research will have a negative effect on participants' welfare, broadly
164 construed. The nature of the harm may be social, behavioural, psychological, physical or
165 economic ([TCPS Glossary](#)).

166 When in doubt about the applicability of this exemption, researchers should consult their REBs.

167 HeLa cell lines

168 The example to which this article applies is the HeLa cell line, which has been in the public
169 domain for decades. The HeLa cell line was derived from tissue obtained without consent from
170 Henrietta Lacks in 1951. It is impossible to seek consent for its use for research because the
171 participant is deceased. The scientific community generally acknowledges that Ms Lacks'
172 contribution to research has been significant. Permitting research involving HeLa cells benefits
173 society while presenting little to no additional research-attributable risk to Ms. Lacks.

174 In the absence of knowing Ms. Lacks' wishes one can look to what is publicly known about the
175 wishes of her relatives. In 2013, the Lacks family entered into an agreement with the U.S.
176 National Institutes of Health (NIH) which lays out the family's expectation that researchers
177 sequencing the whole HeLa genome adhere to the NIH agreement to protect the family's
178 privacy. To respect the Lacks family's wishes, compliance with the NIH agreement should be
179 considered when conducting research involving whole genome sequencing of the HeLa cell line.